Navigation Links
Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Date:9/30/2010

ible," said Steve Harris, Circassia's CEO. "Since the founding of Circassia just four years ago, our ToleroMune(R) technology has successfully completed multiple phase II studies, and we now have four therapies in mid-stage development, targeting some of the most common allergies in the world. As a result, our growing clinical database demonstrates the potential of our novel T-cell vaccines to provide allergy sufferers with short, simple and convenient treatment, whilst minimising the risk of severe and sometimes life-threatening side effects associated with many existing immunotherapies."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's allergy T-cell vaccines show that short treatment regimes can greatly reduce patients' allergic reactions, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy treatments offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceu
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- The overall research objective was to capture ... use. Most researchers outsource NGS technologies; however, in-house ... the next 12 months. Data accuracy and operating ... instruments. Disease-related research is the dominant use for ... surge, with half of the respondents planning to ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... of scientific research products, recently opened an online ... comprehensive cell culture product lines developed and manufactured ... its online store include Biological Industries’ Nutristem® serum-free, ... and human embryonic stem cell (hESC) culture. ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
Breaking Biology Technology:Global Next-generation Sequencing Trends 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... Sequella, Inc., a clinical-stage biopharmaceutical company focused on ... today announced that it received a $594,661 two-year ... National Institutes of Health (NIH), National Institute of ... of SQ641, Sequella,s lead compound in its capuramycin ...
... Dr. Michael Merzenich , PhD - ... plasticity expert and tech entrepreneur - was formally ... D.C. Also a member of the National Academy of Sciences, ... and doctors in the U.S. who have been selected for ...
... CITY, England, October 12 , ... and Milestones Plus,Royalties , Heptares Therapeutics ... announced today that it has,entered into an option agreement with ... StaR(TM) technology to generate novel,drug leads against a nominated, unspecified ...
Cached Biology Technology:Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 2Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 3Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 3
(Date:9/29/2014)... ALEXANDRIA, Va.September 29, 2014Research!America,s 19th annual Advocacy Awards ... advocates who are trailblazers in advancing medical progress ... our nation. The event will take place on ... Mellon Auditorium in Washington, DC. , The 2015 ... anchor Robin Roberts; Michael Milken, founder of the ...
(Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
(Date:9/29/2014)... Department of Energy Joint Genome Institute (DOE JGI), ... announced that 32 new projects have been selected ... sampling Antarctic lakes to Caribbean waters, and from ... water table in forested watersheds, the CSP 2015 ... science can be extracted. , "These projects ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4Tooth serves as evidence of 220 million-year-old attack 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... produce increases, vegetable and fruit producers are facing ... challenged to examine traditional production practices in order ... A recent focus on both the positive and ... the globe working to find methods that can ...
... Motor commands issued by the brain to activate arm ... led by Professor Silvia Arber at the University of ... Research has now discovered, many neurons in the spinal ... but at the same time also back to the ...
... Drosophila (fruit fly) can be synchronised using vibrations, ... . The results suggest that an animal,s own movements can ... daily rhythms characterising most of our bodily functions including the ... and temperature. Researchers at UCL and Queen Mary, University ...
Cached Biology News:Nitrogen management studied in greenhouse pepper production 2Cc to the brain: How neurons control fine motor behavior of the arm 2Cc to the brain: How neurons control fine motor behavior of the arm 3
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... a regulated environment, Pipette Tracker Pro ... that automates gravimetric pipette calibration and ... meets todays regulatory compliance requirements. Pipette ... that includes a full security implementation, ...
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
Biology Products: